View Older Stories View More Recent Stories

Apr 9, 2018 08:47AM AbbVie (ABBV) Says Upadacitinib Met All Primary, Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in RA
Apr 9, 2018 08:45AM Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
Apr 6, 2018 08:00AM AbbVie to Host First-Quarter 2018 Earnings Conference Call
Apr 5, 2018 08:11AM AbbVie (ABBV) Confirms Resolution of HUMIRA Patent Disputes with Samsung Bioepis
Apr 5, 2018 08:09AM Biogen (BIIB) & Samsung Bioepis Report Settlement with AbbVie (ABBV) for Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe
Apr 5, 2018 08:05AM Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe
Apr 5, 2018 08:05AM AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis
Mar 22, 2018 08:46AM AbbVie (ABBV) Announces Results from Phase 2 Study Evaluating Rova-T for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory SCLC
Mar 22, 2018 08:45AM AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer
Mar 21, 2018 09:00AM AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma
Mar 13, 2018 08:01AM AbbVie (ABBV) Says Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Primary Endpoint
Mar 13, 2018 08:00AM AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Mar 5, 2018 08:00AM Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month
Mar 2, 2018 05:56AM AbbVie (ABBV) & Biogen (BIIB) Report Voluntary Global Withdrawal of Marketing Authorizations for ZINBRYTA (Daclizumab)
Mar 2, 2018 05:07AM Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
Feb 26, 2018 08:00AM AbbVie to Present at the Barclays Global Healthcare Conference
Feb 22, 2018 08:00AM AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference
Feb 21, 2018 08:01AM AbbVie (ABBV) Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Its Primary Endpoint
Feb 21, 2018 08:00AM AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Feb 20, 2018 07:03AM Voyager Therapeutics (VYGR), AbbVie (ABBV) Enter Pact to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
Feb 20, 2018 07:00AM AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases
Feb 20, 2018 07:00AM Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
Feb 20, 2018 05:49AM AbbVie (ABBV) Announced New Positive Results from Phase 2b Data on Upadacitinib in Atopic Dermatitis
Feb 17, 2018 04:50PM AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
Feb 17, 2018 04:00PM AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018 11:21AM AbbVie (ABBV) Reports New Phase 2 Data for Upadacitinib Showing Clinical & Endoscopic Outcomes in Crohn's Disease at 52 Weeks
Feb 16, 2018 11:20AM AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
Feb 15, 2018 12:49PM AbbVie Increases Dividend and Announces New Stock Repurchase Program
Feb 14, 2018 05:45PM Glenview Capital 13F Shows New Stakes in Allergan (AGN), Newell (NWL), Charter (CHTR) Aramark (ARMK) (More...)
Feb 12, 2018 08:04AM AbbVie (ABBV) Showcases New, Late-Breaking Investigational Data at AAD Meeting
Feb 12, 2018 08:00AM AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting
Jan 26, 2018 07:51AM AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results
Jan 12, 2018 08:00AM AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call
Jan 8, 2018 08:09AM AbbVie (ABBV) Says Upadacitinib Granted Breakthrough Therapy Designation FDA for Atopic Dermatitis
Jan 8, 2018 08:00AM AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
Dec 20, 2017 08:02AM AbbVie's (ABBV) Upadacitinib Phase 3 Rheumatoid Arthritis Study Meets All Primary and Key Secondary Endpoints
Dec 20, 2017 08:00AM AbbVie to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 20, 2017 08:00AM AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
Dec 19, 2017 08:00AM AbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top
Dec 12, 2017 07:31AM AbbVie (ABBV) Phase 3 Study of VENCLEXTA/ VENCLYXTO in Combination with Rituxan Meets Primary Endpoint
Dec 12, 2017 07:30AM AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
Dec 11, 2017 10:00AM IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
Dec 11, 2017 06:19AM Janssen Research & Development (JNJ) Reports Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5-Yr Follow-Up Data of IMBRUVICA (ibrutinib)
Dec 11, 2017 06:15AM AbbVie (ABBV) Announces Updated 3-Yr Follow-Up Data on RESONATE-2 study (PCYC-1115/1116); IMBRUVICA (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes
Dec 9, 2017 12:03PM IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Dec 9, 2017 09:00AM IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
Dec 5, 2017 08:01AM AbbVie (ABBV) Announces IMBRUVICA Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenstrom's Macroglobulinemia Met Primary Endpoint
Dec 5, 2017 08:00AM IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint
Dec 4, 2017 08:10AM AbbVie (ABBV) Says Risankizumab Met All Primary Endpoints in Fourth Pivotal Phase 3 Psoriasis Study
Dec 4, 2017 08:03AM Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
View More Recent Stories View Older Stories